Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial

Gara Arteaga-Henríquez 1, Silvia Karina Rosales-Ortiz 1, Alejandro Arias-Vásquez 2,3, Istvan Bitter 4, Ylva Ginsberg 5, Pol Ibañez-Jimenez 1, Tünde Kilencz 4, Catharina Lavebratt 6,7, Silke Matura 8, Andreas Reif 8, Janos Rethelyi 9, Vanesa Richarte 1,9,10,11, Nanda Rommelse 3,12, Anne Siegl 8 and J. Antoni Ramos-Quiroga 1,9,10,11*

Abstract

Background: Impulsivity and compulsivity are related to emotional and social maladjustment and often underlie psychiatric disorders. Recently, alterations in microbiota composition have been shown to have implications for brain development and social behavior via the microbiota–gut–brain axis. However, the exact mechanisms are not fully identified. Recent evidence suggests the modulatory effect of synbiotics on gut microbiota and the contribution of these agents in ameliorating symptoms of many psychiatric diseases. To date, no randomized controlled trial has been performed to establish the feasibility and efficacy of this intervention targeting the reduction of impulsivity and compulsivity. We hypothesize that supplementation with synbiotics may be an effective treatment in adults with high levels of impulsivity and/or compulsivity.

Methods/design: This is a prospective, multicenter, double-blind, randomized controlled trial with two arms: treatment with a synbiotic formula versus placebo treatment. The primary outcome is the response rate at the end of the placebo-controlled phase (response defined as a Clinical Global Impression–Improvement Scale score of 1 or 2 = very much improved or much improved, plus a reduction in the Affective Reactivity Index total score of at least 30% compared with baseline). A total of 180 participants with highly impulsive behavior and a diagnosis of attention deficit/hyperactivity disorder (ADHD) and/or borderline personality disorder, aged 18–65 years old, will be screened at three study centers. Secondary outcome measures, including changes in general psychopathology, ADHD symptoms, neurocognitive function, somatic parameters, physical activity, nutritional intake, and health-related quality of life, will be explored at assessments before, during, and at the end of the intervention. The effect of the intervention on genetics, microbiota, and several blood biomarkers will also be assessed. Gastrointestinal symptoms and somatic complaints will additionally be explored at 1-week follow-up.

Discussion: This is the first randomized controlled trial to determine the effects of supplementation with synbiotics on reducing impulsive and compulsive behavior. This clinical trial can contribute to explaining the mechanisms involved in the crosstalk between the intestinal microbiome and the brain. If effects can be established by reducing impulsive and compulsive behavior, new cost-effective treatments might become available to these patients.

(Continued on next page)
Background
Impulsivity may be defined as “a predisposition towards rapid, unplanned reactions to internal or external stimuli, with diminished regard to the negative consequences that such reactions may have for the impulsive individual or others” [1–4]. In contrast, compulsivity represents “the performance of repetitive and functionally impairing overt or covert behavior without an adaptive function, performed in a habitual or stereotyped fashion, either according to rigid rules or as a means of avoiding perceived negative consequences” [2, 5]. Both traits share neuronal mechanisms involving a dysfunctional inhibition of thoughts and behavior [1, 6], and, rather than unitary phenomena, they are considered as multidimensional constructs that involve disruption within a range of neural processes, including attention, perception, and coordination of motor and/or cognitive processes. Impulsive and compulsive symptoms are overrepresented in individuals with several psychiatric disorders, such as attention-deficit/hyperactivity disorder (ADHD), borderline personality disorder (BPD), and/or obsessive-compulsive disorder [7]. Importantly, maladaptive impulsivity and compulsivity can lead to serious consequences not only for affected individuals and their families but also for society. They predispose individuals to aggressive or addictive behaviors, increasing the risk for mortality [8]. Despite this, data about modifiable risk and protective factors are largely lacking.

Nutrition, brain, and behavior
Not only heritability, sex, and socioeconomic status (SES) but also diet may play a pivotal role in impulsive and compulsive symptomatology [9, 10]. In line with this, a number of studies have shown that different nutrient combinations may have interactive effects on cognitive function and behavior, including antioxidants; omega-3 polyunsaturated fatty acids (PUFAs); monounsaturated fatty acids; polyphenols; potassium; calcium; zinc; fiber; folate; and/or vitamins A, B12, C, D, or E [11–13]. More specifically, recent reports have linked aggressive behavior with low blood omega-3 PUFA levels and/or with low seafood consumption [14], and several animal studies have found that the long-term consumption of a low-calorie diet enhances autophagy and protects neurons effectively against aging, maintaining learning and memory capacity, whereas long-term consumption of a high-calorie diet facilitates neuronal loss in the hippocampus, aggravating age-related cognitive impairments [15, 16]. Importantly, the type of food intake can influence brain development and function in all age groups, with a recent study showing that prenatal exposure to an unhealthy diet was associated with ADHD symptoms, further linked to altered epigenetic modification of blood-derived DNA [17, 18]. However, these findings have not been consistently replicated in large-sample randomized controlled trials (RCTs), and the underlying mechanisms remain unknown [19–23].

Gut microbiome, microbiota, and behavior
Although microbiota refers to the specific microorganisms that are found within a specific environment, microbiome refers to the collection of genomes from all the microorganisms found in this particular environment [24]. It is hypothesized that an imbalance in the gut microbiota (dysbiosis) may have a negative effect on neurodevelopment, behavior, and cognition [25–31]. Related to this, changes in human microbiome and/or microbiota composition have been consistently found in individuals with autism spectrum disorder (ASD) [32–36], and a pilot study on the microbiome has demonstrated, for the first time, a difference in several bacterial taxa between subjects with ADHD and healthy control subjects [37]. Specifically, lower Firmicutes genus and higher Bifidobacterium genus were found in subjects with ADHD than in healthy individuals, with the increase in the Bifidobacterium genus relating to decreased ventral striatal functional magnetic resonance imagining responses during reward anticipation [37].

The relationship between gut microbiota and the brain seems to be bidirectional. The gut microbiota modulates brain function and development, and the brain can alter the gut microbiota, allowing colonization by pathogenic bacteria [38–40]. Illustrating this idea, some studies have shown an overrepresentation of gastrointestinal symptoms in patients with both neurodevelopmental and neuropsychiatric disorders [41–48], and a study in healthy students found that during exams, psychological stress increased at the same time that numbers of lactobacilli in stool samples decreased [49].

But how does this bidirectional communication—the gut–brain axis—work? The “enteric nervous system” is complex and, regarding neurotransmitters and signaling molecules, similar to the brain [50]. As an example, 95% of all circulating serotonin, dopamine, or noradrenaline precursors are produced by our gut microbiota [50]. This system is connected to the central nervous system.
through hormonal or innate neuronal pathways [51] that are critical for its development and vice versa [52]. Furthermore, studies have shown that the gut flora is critically involved in immunoregulation [53–55], whereas some reports have shown the immune system as an important regulator of neurodevelopment and synaptic function in the brain [56]. In line with this, immune dysfunction and/or autoimmunity have been speculated to be associated with many neuropsychiatric and neurodevelopmental disorders, such as ADHD [57, 58]. Supporting this idea, an increased incidence of immune-mediated disorders (e.g., asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, psoriasis, thyrotoxicosis, or type 1 diabetes) has been found among patients with ADHD [59–62]. Moreover, elevated inflammatory markers (especially interleukin [IL]-6) [63–65] or auto-antibody levels (e.g., anti–basal ganglia antibodies, antibodies against the dopamine transporter) [66, 67] have been found both in serum/plasma and in cerebrospinal fluid of these patients [63, 68, 69].

Probiotic/synbiotic interventions

Probiotic bacteria, or “probiotics,” are live, nonpathogenic microorganisms that normally inhabit the intestines and contribute to the health of the host by improving microbial balance [70]. On the other hand, prebiotics are nondigestible ingredients that selectively stimulate the growth and activity of these probiotic microorganisms [71]. The synergic combination of probiotics and prebiotics is referred to as synbiotics. Recent findings suggest that probiotics and/or synbiotics can not only revert dysbiosis but also modulate brain activity and improve cognition, mood, and behavior [72–78]. Importantly, a recent study has shown that oral administration with Lactobacillus during the first 6 months of life reduced the prevalence of ADHD or ASD at the age of 13 [79]. However, the exact mechanisms by which probiotics and/or synbiotics exert their action remain unknown. Recent findings suggest immunomodulatory and anti-inflammatory properties of these agents [80], possibly by selectively targeting T-helper (Th) type 1 [81] and Th17 cell lineages [82].

The aim of the present multicenter, prospective, double-blind, placebo-controlled, parallel-group study is to investigate the effect of a synbiotic formula (Symbiotic 2000 Forte 400; Symbiotic AB, Höganäs, Sweden) on reducing impulsive, compulsive, and aggressive behaviors in a sample of highly impulsive adults with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) and/or borderline personality disorder (BPD). In this study, we will test the idea that supplementation with probiotics will, by modifying the gut microbiota structure and metabolism, reduce impulsive, compulsive, and aggressive behaviors in this specific population and thereby improve their daily life function. Moreover, we will evaluate the composition of gut microbiota in this population and link it to inflammatory/immunological abnormalities that can underlie core symptoms of these disorders.

Methods/design

This protocol is presented in accordance with the 2013 SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement (See Additional file 1 for the populated SPIRIT Checklist [83]).

Trial design and study setting

The Treatment of impulsivity in adults with probiotics (PROBIA) trial is designed as a 10-week multicenter, prospective, randomized, double-blind, placebo-controlled, parallel design study. It will be performed in close cooperation between three European clinical centers: Goethe University Hospital Frankfurt (Department of Psychiatry, Psychosomatic Medicine and Psychotherapy), Frankfurt, Germany; Vall d’Hebron Research Institute (Psychiatry, Mental Health and Addictions Group), Barcelona, Spain; and Semmelweis University (Department of Psychiatry and Psychotherapy), Budapest, Hungary. These centers are all affiliated with or part of university hospitals and, with around 300 new inpatients and outpatients visiting each center every year, are considered as reference centers for the treatment of ADHD, BPD, and other disorders characterized by high impulsivity levels.

Study population and recruitment

Participants will be eligible for participation in this study if they meet all the inclusion criteria and none of the exclusion criteria listed in Table 1. With the aim of gender balancing the study, at least 30% female participants will be included.

Recruitment began on 22 February 2019 and will have a duration of 2 years. A total of 180 participants (60 subjects per site) will be recruited by trained psychiatrists and/or psychologists at the different sites (see Fig. 1). Strategies aimed at optimizing the recruitment process will include the distribution of handouts or flyers to colleagues, physicians, and families, as well as an offer of reimbursement of study-related travel costs to participants. Furthermore, and depending on local regulations, information via presentations, websites, and social media campaigns will be provided. Regular calls will be made to patients to avoid participant withdrawal from the study.

Randomization and study intervention

After eligibility checks have been conducted and written consent has been obtained by the different psychiatrists and/or psychologists of the trial team, eligible
participants will be randomized to the experimental (EG) or the control (CG) group in a 1:1 allocation ratio using an independent web-based computerized service (www.randomization.com). Randomization will be center-stratified and have a fixed length per center, being independent of participant characteristics. However, due to the large sample size, a balanced ratio of baseline characteristics between the EG and CG is expected.

Individual participant treatment kits will contain all required daily synbiotic or placebo envelopes for the 10-week RCT and will be prepared in advance by sequentially

Table 1 Inclusion and exclusion criteria of the PROBIA trial

| Inclusion criteria | Exclusion criteria |
|--------------------|--------------------|
| Both males and females aged 18–65 years | Antibiotherapy within the last 6 weeks prior to study |
| A high level of multidimensional impulsivity based on both a Clinical Global Impression–Severity Scale (CGI-S) score ≥ 4 and an Affective Reactivity Index (ARI) ≥ 5 | Currently taking probiotics |
| DSM-5 criteria for attention deficit/hyperactivity disorder (ADHD) and/or borderline personality disorder (BPD) confirmed by a structured diagnostic interview (ADHD: Diagnostic Interview for Adult ADHD [DIVA 2.0]; BPD: Structured Clinical Interview for DSM-IV [SCID-II]) | Presence of a major psychiatric disorder with psychotic symptoms or other major psychiatric conditions requiring hospitalization (e.g., significant mood disorders) |
| Deemed reliable and compliant with the protocol by the investigator | Neurological disorders involving central functions (e.g., epilepsy, multiple sclerosis, narcolepsy) |
| Ability to speak and comprehend the native language of the country in which the assessments take place | Intelligence quotient (IQ) < 70 (measured by WAIS, if available) |
| Informed consent signed | Major physical illnesses of the cardiovascular, endocrine, pulmonal, immune, or gastrointestinal system or undergoing immunosuppression |

Abbreviations: DSM Diagnostic and Statistical Manual of Mental Disorders, PROBIA Treatment of impulsivity in adults with probiotics, WAIS Wechsler Adult Intelligence Scale
numbering and labeling them as “A” or “B.” Because this is a double-blind study, neither the participants nor the clinicians involved in the trial will have access to the randomization list.

Symbiotic 2000 Forte 400 (SF) is a synbiotic formula currently produced by Synbiotic AB in Höganas, Sweden. Each dose (powder-containing sachet) of SF contains 100 billion of each of *Pediococcus pentosaceus* 5-33:3, *Lactobacillus paracasei* subsp. *paracasei* 19, *Lactobacillus plantarum 2362*, and *Leuconostoc mesenteroides* 77:1, in combination with four bioactive fermentable fibers (2.5 g each of β-glucan, inulin, pectin, and resistant starch). SF is categorized as a generally regarded as safe agent, being tested on several hundreds of critically ill patients (e.g., pancreatitis, liver transplant) with no side effects or specific and/or relevant risks referred to the trial participants [83]. The placebo (also provided by Synbiotic AB) is composed of the polysaccharide maltodextrin and has a texture and flavor similar to SF. Participants will be asked to continue with their previous medications and/or usual treatments and add the synbiotic or placebo once daily on top of cold foods such as yogurt, muesli, or salad. To secure bacterial viability, participants will be asked to store both SF and placebo at +4–6°C.

**Outcome measures**

**Primary outcomes**

The primary outcome measure will be response to treatment, defined by a reduction in the Affective Reactivity Index—Self-Report (ARI-S) scale total score of at least 30% compared with baseline plus a Clinical Global Impressions—Improvement Scale total score of 1 or 2 (very much improved or much improved) at the end of the placebo-controlled phase.

**Secondary outcomes**

The secondary outcomes are selected to assess intervention effects on symptoms of impulsivity, compulsivity, and aggression via a series of selected scales and questionnaires (e.g., the Strengths and Difficulties Questionnaire, Yale-Brown Obsessive Compulsive Scale, Difficulties in Emotion Regulation Scale, and the Urgency, Premeditation [lack of], Perseverance [lack of], Sensation Seeking, Positive Urgency, Impulsive Behavior Scale [UPPS-P]). Interestingly, the UPPS-P consists of a 59-item self-report assessing five subscales (negative and positive urgency, premeditation, perseverance, and sensation seeking), with a mean value being calculated separately for each scale, allowing the estimation of distinct dimensions of impulsive behavior [84]. Another secondary outcome measure will be the change in ADHD symptoms (via the ADHD Rating Scale [ADHD-RS]). Like the UPPS-P, the ADHD-RS provides not only a total ADHD score but also separate scores for inattentive, hyperactive, and impulsive subscales, providing a better characterization of patients.

Changes in general psychopathology, major stressors, neurocognitive function, sleep disturbances, body-related measures (e.g., pulse rate, blood pressure, body mass index, waist–hip circumference ratio), medications taken, physical activity (via mobile health application and movement sensors), health-related quality of life, microbiome composition, and blood markers will also be evaluated. Blood markers will include genetic parameters, hormones, neuromarkers, nutrients, and inflammatory molecules (see Table 2).

Blood samples (34.5 ml) will be fractioned into serum and plasma and stored at −80°C. Then, they will be shipped to the Department of Human Genetics of Radboudumc, Nijmegen, The Netherlands, for storage. Thereafter, blood markers will be measured at the Department of Clinical Biochemistry at Radboudumc in Nijmegen according to validated protocols. Participants willing to take part in the assessment of their microbiome will receive a specially designed container for feces collection, allowing participants to send the samples by ordinary post to the individual centers, where they will be processed and stored at −80°C for later shipping to the Department of Human Genetics of Radboudumc for sequencing and analysis of bacterial DNA. Crucially, before and during the intervention, the participants will be asked to send back their fecal samples within 24 h after the test sessions.

Another secondary outcome measure will be the change in nutritional intake. Participants will be asked to complete at least three 24-h dietary recalls (24HDRs): at baseline, during the intervention, and directly afterward, including two weekdays and one weekend day on nonconsecutive days. They will need to describe the type and amount (in grams) of all drinks and foods consumed during the previous days, starting with the first intake after waking up in the morning. Moreover, they will have to specify the time for every meal occasion during the day (breakfast, lunch, dinner, or snack).

Participant compliance with the intervention (SF or placebo) will be monitored with the Probabilistic Medication Adherence Scale throughout the 10 weeks of the intervention. Moreover, participants will be asked to return unused envelopes from the previous visit. This will enable us to secure bacterial viability and at the same time estimate adherence to treatment. Finally, the presence of somatic complaints/side effects or gastrointestinal symptoms (via the Bristol Stool Scale) will also be evaluated.

**Participant timeline**

The trial timeline is shown in Table 3. Time points per intervention will be selected on the basis of known duration to exert effect.
At the screening visit (TS), the rate of impulsivity will be established by performing structured interviews, the ARI-S, and the Clinical Global Impression–Severity Scale. After having established the presence of high impulsivity, the diagnosis of ADHD and/or BPD will be assessed via the Diagnostic Interview for Adult ADHD, Second Edition, and the Structured Clinical Interview for DSM-IV Axis II Disorders section for BPD, respectively. Thereafter, screening for eligibility based on clinical history, demographics (including SES), tests, and questionnaires (e.g., Mini-International Neuropsychiatric Interview [M.I.N.I.-Plus], IQ tests [Wechsler Adult Intelligence Scale, Fourth Edition]) will be performed, and informed consent will be obtained. Once this process is finished, a mobile health system as well as a food record will be introduced to participants (duration, approximately 1 h). The mobile health system will enable patients to share (via a mobile application) data of interest regarding their physical activity (acceleration, number of steps).

Trial-specific assessments will be done at T0 (duration, approximately 3 h), scheduled within 1 week after TS. During the week between TS and the baseline visit (T0), the mobile health system will be used at home. Here and during 24 h, participants will wear movement sensors on two working days and on Saturday and Sunday, and they will be asked to complete three 24HDRs on a web-based tool or paper on two nonconsecutive weekdays and one weekend day (duration, 15 min each). Individuals will also be asked to collect feces on one day during the 1-week period at home and to bring it along at T0.

In addition to responding to the questionnaires and scales listed in Table 1, participants will be instructed on how to store and eat the study product (SF or placebo). The intervention will begin on the day after T0, and participants will be asked to continue with their usual medications and/or treatments. Participants will have to complete another three 24HDRs, collect their feces 1 week before T2 and bring it along at T2. At 10 weeks after initiating the probiotic or placebo intervention (T2), primary and some secondary outcome measures will be assessed again (duration, approximately 3 h).

Within 1 week after T2 and with the aim of measuring safety aspects of the intervention (i.e., somatic complaints/side effects as well as gastrointestinal symptoms),

### Table 2 Measurement of blood markers

| Type of marker | Marker name | Link with: | Tissue          |
|---------------|-------------|------------|-----------------|
| Inflammation  | TNF-α       | Inflammation/exercise*/diet | Serum/plasma    |
|               | IL-1β       | Inflammation/exercise*/diet | Serum/plasma    |
|               | IL-6        | Inflammation/exercise*/diet | Serum/plasma    |
|               | CRP         | Inflammation/diet            | Serum/plasma    |
|               | Bacterial lipoprotein | Inflammation/diet | Serum/plasma |
|               | Vitamin B₁₂ | Diet                   | Serum/plasma    |
|               | Folic acid  | Diet                   | Serum/plasma    |
| Vitamins and minerals | Vitamin D | Diet                   | Serum/plasma    |
|               | Iron        | Diet                   | Serum/plasma    |
|               | Cu          | Diet                   | Serum/plasma    |
| Nutrients     | Cholesterol | Diet                   | Serum/plasma    |
|               | Glucose     | Diet                   | Serum/plasma    |
|               | Homocysteine| Diet                   | Serum/plasma    |
|               | BDNF        | Diet                   | Serum/plasma    |
|               | 5-HT        | Diet                   | Serum/plasma    |
| Other markers | SCFA        | Diet                   | Feces           |
|               | GLP-1       | Hormone-diet           | Serum/plasma    |
|               | Insulin     | Hormone-diet           | Serum/plasma    |
|               | Paraoxonase | Diet                   | Serum/plasma    |

Abbreviations: 5-HT serotonin, BDNF brain-derived neurotrophic factor, CRP C-reactive protein, GLP-1 glucagon-like peptide 1, IL interleukin, SCFA short-chain fatty acid, TNF-α tumor necrosis factor-α.
### Table 3: Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schematic schedule of enrollment, interventions, and assessments

| Study procedures | Screening | Open label | Follow-up |
|------------------|-----------|------------|-----------|
| Visit            | TS T0 T1 T2 T3 |
| Week             | −1 1 5 10 11 |
| Day              | −7 to −1 1 35 ± 2 70 ± 2 77 ± 2 |

- **Informed consent form**
  - X
- **Inclusion/exclusion criteria**
  - X
- **Demographics (including SES)**
  - X
- **IQ (IQ score based on WAIS, if available)**
  - X
- **M.I.N.I.-Plus assessment**
  - X
- **Confirmation of diagnosis/es**
  - DIVA 2.0
  - X
- **Confirmation of ADHD**
  - ADHD-RS
  - X
- **Confirmation of BPD**
  - SCID-II
  - X

#### Primary outcome
- **Clinical Global Impression–Improvement Scale**
  - CGI-I
  - X
  - X
  - X
  - X
- **Affective Reactivity Index**
  - ARI-S
  - X
  - X
  - X
  - X

#### Secondary outcomes
- **Clinical Global Impression–Severity Scale**
  - CGI-S
  - X
  - X
  - X
  - X
- **Clinician rating of ADHD symptoms**
  - ADHD-RS
  - X
  - X
- **Self-rating of multidimensional impulsivity**
  - UPPS-P
  - X
  - X
- **Questionnaire on well-being**
  - X
- **Functioning Assessment Short Test**
  - FAST
  - X
  - X
- **Self/other rating of strength and difficulties**
  - SDQ
  - X
  - X
- **Clinician rating of compulsivity**
  - Y-BOCS
  - X
  - X
- **Sleep problems**
  - S-item questionnaire
  - X
  - X
- **Self-rating of emotion regulation difficulties**
  - DERS-16
  - X
  - X
- **Somatic complaints/side effects**
  - Body system questions
  - X
  - X
- **Gastrointestinal symptoms**
  - Bristol Stool Scale
  - X
  - X
  - X
- **Self-rating of perceived stress**
  - PSS
  - X
  - X
- **Major stressors**
  - X
  - X
- **Blood pressure, pulse rate, height, weight, waist, hip, medical history, medication evaluation**
  - Assessed by clinician
  - X
  - X
  - X
- **Physical activity**
  - Actigraphy, mobile health application
  - X
  - X
- **Blood biomarkers**
  - Blood sample
  - X
  - X
- **Microbiome**
  - Stool sample
  - X
  - X
- **DNA and RNA**
  - Blood sample
  - X
  - X
- **Neurocognitive measures**
  - CPT-II
  - X
  - X
- **Nutritional intake**
  - Food diary
  - X
  - X
- **Treatment adherence/satisfaction/beliefs**
  - Probabilistic Medication Adherence Scale
  - ProMAS
  - X
  - X

**Abbreviations:** ADHD attention-deficit/hyperactivity disorder, ADHD-RS Attention-Deficit/Hyperactivity Disorder Rating Scale, ARI-S Affective Reactivity Index–Self-Report, BPD borderline personality disorder, CGI-I Clinical Global Impression–Improvement Scale, CGI-S Clinical Global Impression–Severity Scale, CPT-II Continuous Performance Test, DERS-16 Difficulties in Emotion Regulation Scale, DIVA 2.0 Diagnostic Interview for Adult ADHD, Second Edition, FAST Functioning Assessment Short Test, IQ intelligence quotient, M.I.N.I.-Plus Mini-International Neuropsychiatric Interview, PROBIA Treatment of impulsivity in adults with probiotics, ProMAS Probabilistic Medication Adherence Scale, PSS Perceived Stress Scale, SCID-II Structured Clinical Interview for DSM-IV Axis II Disorders, SDQ Strengths and Difficulties Questionnaire, SES socioeconomic status, UPPS-P Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale, WAIS Wechsler Adult Intelligence Scale, Y-BOCS Yale-Brown Obsessive Compulsive Scale
the follow-up (T3) assessment will take place (duration, approximately 20 min).

Criteria for discontinuing allocated interventions
Any undesirable experience (of either a physical or psychological nature) occurring to a participant during the study, whether or not considered related to undergoing treatment with SF or placebo, will be considered an adverse event (AE). Participants will be asked for AEs at each visit and then will be discussed with the study physician at the site. Thus, if an AE occurs in response to SF or placebo, this will immediately be recorded by the principal investigator (PI) or the PI’s staff, and the participant may be discontinued from the study.

Serious adverse events (SAEs), serious adverse reactions (SARs) or unexpected serious adverse reactions are defined, respectively, as any adverse event, reaction, or unexpected adverse reaction that results in death; is life-threatening and/or requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; or consists of a congenital anomaly or birth defect. Any of them will be communicated immediately to the lead coordinator of the trial at Vall d’Hebron Research Institute (VHIR) and to the coordinating PI at the clinical site, who will be responsible for reporting the event to the ethics committee that approved the protocol. Suspected unexpected serious adverse reactions (SUSARs) that are fatal or life-threatening must also be reported not later than 7 days after the sponsor is first made aware of the reaction. Any additional relevant information must be reported within 8 days. SUSARs that are not fatal or life-threatening must be reported within 15 days of the sponsor first becoming aware of the reaction. All ongoing AEs will be followed up until no more signs and symptoms are verifiable or until stability has been reached. Depending on the event, additional tests or medical procedures, as well as referrals to a general physician or a medical specialist, will be indicated during this follow-up phase.

In the case that a participant’s psychological state deteriorates to a clinically significant degree during the trial, the investigators will either discuss with the participant the possibility of withdrawing from the study or decide that the participant should withdraw. If a participant, for any reason, requires treatment with certain therapeutic agents (i.e., antibiotics), the agent taken and time of administration will be noted. If any other protocol exclusion violation has occurred, the participant’s involvement will be discontinued. Participants may at any time request to be withdrawn from the study or revoke their consent to participate. If a patient is discontinued from the trial, a follow-up visit will be carried out to ensure the well-being of the participant.

Data management
Participants and clinical staff will be able to fill out all requested questionnaires online via the Castor database system (http://castoredc.com/). Then, data will be directly uploaded to a central database using a macro software. Both the Castor database system and macro software are fully secure and in accordance with current standards (i.e., Good Clinical Practice [GCP], 21 CFR Part 11, EU Data Protection Directive, ISO27001 and ISO9001 hosting). Both systems are also approved by the Clinical Research Centre Nijmegen, Nijmegen, The Netherlands, because it will be responsible for tracking any changes made manually to raw data. Any other data will be uploaded (after site-specific quality control) by the research team to the central database using encrypted mass storage devices. All information collected in the study will be coded with a unique pseudo-code identifier (PSC) in such a way that participants cannot be identified from the corresponding data (directive 95/46/EC) and ensuring that the information collected for the study remains strictly confidential. Likewise, collected samples of biomaterial (i.e., blood and microbiota) will be labeled with the corresponding PSC. All patient-related data will be stored at the clinical sites in a database with password protection. A separate single database on the central server of VHIR will link the PSC to the participant’s personal data (including name, address, telephone details, and date of birth). Databases will be accessible only to the immediate research team at each site.

Study monitoring
Proper conduct of data collection in the trial will be monitored via on-site visits of a monitoring staff member throughout the study; quality of data collected will further be monitored regularly by a statistical supervision team. After the first five participants per site are included, the quality of data (on item/trial level) per participant will be checked, aiming at detecting any error that may occur in the beginning of the project and to prevent these errors from recurring. After including participant numbers 5 to 10, the completeness and accuracy of the data on summary/scale level will be checked for all participants. Thereafter, data on a summary/scale level will be checked randomly for 1 in 5 participants. Outcomes of this data check will be written in an overview and reported to all research personnel. If adjustments to the database or procedures need to be made, these will be made as soon as possible. Moreover, the investigators will permit quality data checks, audits, and inspections by providing the sponsor direct access to source data and other documents (e.g., medical files) by request.

In each participating center, the PI will be responsible for the local ethics application, on-site training of
clinicians, identification and recruitment of participants including randomization, data collection according to the study protocol, completion of the case report forms including answering queries, maintaining and updating the investigator site file, participation in monitoring, and reporting SAEs to the study PI in Barcelona. Each site will have regular meetings with their clinical team in order to ensure progress of the trial. As the leading coordinator center and with the aim of monitoring the study progress, the VHIR team will arrange telephone meetings with the local sites throughout the project on a regular basis.

Due to the need for research groups to share their data to maximize the value of each research contribution, to pool them to address research questions that require larger numbers, or to carry out meta-analyses, participants and, if applicable, their legal guardians will be asked whether they consent that their data (or portions of their data) will be shared in anonymized fashion with other research projects.

Statistical analysis
Primary outcome measures will be analyzed by applying logistic regression analyses with type of treatment, diagnostic group (e.g., ADHD, BPD, or both), gender, and center as independent variables. A sample size of 180 participants will allow for detection of an odds ratio of 2.55 with 90% power, assuming a response rate of 20% for the CG at a significance level of 0.05. For simplification purposes, calculations will assume no effects of the covariates on the response rate. Secondary analyses will be performed on the secondary outcome measures assessed at the different time points. General linear models will be applied to examine effects of treatment group on continuous outcome variables while controlling for baseline assessment, gender, diagnostic group, and center. Categorical outcome measures will be investigated using generalized linear models. Treatment effects and their 95% confidence intervals will be reported. To investigate potential long-term effects of probiotics, data of the EG for 10 weeks will be analyzed. General linear models for repeated measurements will be applied to study changes from baseline to follow-up visit for this group, and missing data will be handled by the last observation carried forward method. Statistical significance will be defined at the 0.05 level.

Once the primary and secondary outcome measures results are obtained, all responsible investigators at all study sites will get access to the data to be able to reanalyze the data regarding specific additional research questions.

In case of an external request for replication, the respective statistical analysis will be provided by the trial statistician.

Ethics and dissemination
Before the first subject is enrolled in the trial, all ethical and legal requirements will be met. The study protocol, participant information, and the respective consent form will be approved according to the respective local and national regulations at each of the participating centers before the start of the trial, and participants will be made aware of the investigational nature and the core aspects of the study as well. This study will be conducted in accordance with the principles of the Declaration of Helsinki (2008) and the Medical Research Involving Human Subjects Act (WMO). It will follow the principles of the Guideline for Good Clinical Practice (ICH GCP guideline E6), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines in the participating countries/regions. The handling of personal data will be done in accordance with the new General Data Protection Regulation that started in May 2018 in the European Union.

Trial findings will be reported to public and private healthcare providers, specific stakeholders such as policy makers, the medical community, or academic and commercial parties interested in therapy development, as well as the general public via publications, conferences, press releases, public talks, and the internet—(e.g., YouTube, Facebook, Twitter). All trial results will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines (www.consort-statement.org).

Discussion
We have presented a design and protocol for an RCT of a nonpharmacological intervention—symbiotic treatment—for the reduction of impulsive and compulsive symptomatology in a sample of adult patients with ADHD and/or BPD. The PROBIA study is the first multinational RCT evaluating the effects of probiotics on cognitive function, impulsivity, and compulsivity in a large ADHD and/or BPD sample. Existing studies primarily addressing the effects of supplementation with probiotics in psychiatric disorders mostly come from animal studies or have been done in smaller samples. Moreover, to date, no RCT has evaluated the composition of gut microbiota in ADHD and/or BPD populations with a large sample size. Thus, whether the microbial community in these individuals is different from that in mentally healthy humans remains unknown.

Our study will also allow us to identify links between the microbiome and hallmark characteristics of ADHD and/or BPD patients (e.g., impulsivity, compulsivity, or aggressive behavior) and also to investigate whether dietary patterns and probiotics can induce alterations in the gut microbiota, which may mediate/moderate effects on these behaviors. Linking these data with blood biomarkers as well as genetic
and epigenetic parameters will provide integrated mechanistic knowledge on diet/lifestyle–gut–brain–behavior relationships relevant to impulsivity and compulsivity. In order to create a study sample population that is highly representative of impulsivity, broad inclusion criteria will be applied, with most psychiatric comorbidities being accepted, allowing us to provide a better illustration of possible effects that could be expected if the intervention were introduced in a clinical setting. Understanding the microbiota would be important both for better comprehension of the biological bases that underlie the studied disorders and for the future development of new evidenced-based medications for these conditions.

**Trial status**

This trial is registered with ClinicalTrials.gov (NCT03495375) and was first posted on 12 April 2018. The first participant gave consent on 22 February 2019 and was randomized on 27 February 2019. Recruitment is expected to be completed 1 April 2021. The most recent version of the protocol (V2.0) was approved by the Ethical Committee of the University Hospital Vall d’Hebron, Barcelona, Spain, on 12 April 2019 [PR (AG)311-2018].

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-019-4040-x.

**Additional file 1.** Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 checklist: recommended items to address in a clinical trial protocol and related documents.

**Abbreviations**

24HDR: 24-h dietary recall; ADHD: Attention-deficit/hyperactivity disorder; ADHD-RS: Attention-Deficit/Hyperactivity Disorder Rating Scale; AE: Adverse event; ARI-S: Affective Reactivity Index–Self-Report; ASD: Autism spectrum disorder; BPD: Borderline personality disorder; CGI-I: Clinical Global Impression–Improvement Scale; CGI-S: Clinical Global Impression–Severity Scale; CPT-Il: Continuous Performance Test; DERS-16: Difficulties in Emotion Regulation Scale; DIVA 2.0: Diagnostic Interview for Adult ADHD, Second Edition; EG: Experimental group (probiotic); GCP: Good clinical practice; IL: Interleukin; IQ: Intelligence quotient; LAB: Lactic acid bacteria; M.I.N.I.-Plus: Mini-International Neuropsychiatric Interview; PI: Principal investigator; ProMAS: Probabilistic Medication Adherence Scale; PSC: Pseudocode identifier; PUFA: Polyunsaturated fatty acid; RCT: Randomized controlled trial; SAE: Serious adverse event; SCID-II: Structured Clinical Interview for DSM-IV Axis II Disorders; SDQ: Strengths and Difficulties Questionnaire; CGI-I: Clinical Global Impression–Severity Scale; CPT-Il: Continuous Performance Test; DERS-16: Difficulties in Emotion Regulation Scale; DIVA 2.0: Diagnostic Interview for Adult ADHD, Second Edition; EG: Experimental group (probiotic); GCP: Good clinical practice; IL: Interleukin; IQ: Intelligence quotient; LAB: Lactic acid bacteria; M.I.N.I.-Plus: Mini-International Neuropsychiatric Interview; PI: Principal investigator; ProMAS: Probabilistic Medication Adherence Scale; PSC: Pseudocode identifier; PUFA: Polyunsaturated fatty acid; RCT: Randomized controlled trial; SAE: Serious adverse event; SCID-II: Structured Clinical Interview for DSM-IV Axis II Disorders; SDQ: Strengths and Difficulties Questionnaire; SES: Socioeconomic status; SF: Symbiotic 2000 Forte; SUSAR: Suspected unexpected serious adverse reaction; UPPS-P: Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale; Y-BOCS: Yale-Brown Obsessive Compulsive Scale

**Acknowledgements**

Not applicable.

**Authors’ contributions**

GAH and SKRO drafted the manuscript. JR, JY, GCLARAS, and JARQ critically reviewed the manuscript. All other authors read and approved the final version of the manuscript.

**Funding**

The project is sponsored by the European Commission and funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 728018. The sponsors and funders played no part in study design; collection, management, analysis, and interpretation of the data; writing of the report; or the decision to submit the report for publication.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Written consent will be obtained from every study participant. The Ethical Committee of the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at the University Hospital Frankfurt-Goethe University in Frankfurt, Germany, approved the study protocol on 14 November 2018 with protocol number 269/18. The ethical committee approval for the study protocol requested by Istvan Bitter, Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary, was issued by the Ministry of Human Capacities, dated 3 September 2019. The Ethical Committee of the University Hospital Vall d’Hebron in Barcelona, Spain, approved the study protocol on 11 January 2019 with protocol number 311/2018. An addendum was approved on 12 April 2019 with protocol number 311/2018.

**Consent for publication**

Not applicable.

**Competing interests**

IB has served as an advisor/consultant in the last 5 years for Angeli, Eli Lilly, Gedeon Richter, and Pierre Fabre and has lectured for Eli Lilly, Janssen, Lundbeck, Gedeon Richter, and Servier. JARQ was on the speaker’s bureau and/or acted as consultant for Eli Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Lundbeck, Almirall, Braingaze, Sincrolab, Medice and Rubio in the last 5 years. He has also received travel awards (air-tickets + hotel accommodation) for taking part in psychiatric meetings organized by Janssen-Cilag, Rubio, Shire, Medice and Eli Lilly. The Department of Psychiatry, chaired by him, has received unrestricted educational and research support from Eli Lilly, Lundbeck, Janssen-Cilag, Actelion, Shire, Ferrer, Orlyon, Roche, Psiou and Rubio in the last 5 years. YG has received speaker fees, has received reimbursement for travel costs, and/or has served as a consultant for Novartis, HB Pharma, Shire, Eli Lilly, Hogefie, Broadman, Clarke Partners, Mediscie, Medi-bas, and Natur & Kultur. All other authors declare that they have no competing interests.

**Author details**

1Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Catalonia, Spain. 2Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands. 3Department of Psychiatry, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands. 4Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. 5Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institute, Stockholm, Sweden. 6Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. 7Center for Molecular Medicine (CMMI), Karolinska University Hospital, Stockholm, Sweden. 8Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Frankfurt, Germany. 9Group of Psychiatry, Mental Health and Addictions, Vall d’Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain. 10Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain. 11Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. 12Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands.

Received: 13 May 2019 Accepted: 30 December 2019 Published online: 11 February 2020

**References**

1. Fineberg NA, Chamberlain SR, Goodin a AE, Stein DJ, Vanderschuren LJ, Gillan CM, et al. New developments in human neurocognition: clinical,
genetic, and brain imaging correlates of impulsivity and compulsivity. CNS Spectr. 2014;19(1):69–89.

2. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A, et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology. 2010;35(3):591–604.

3. Potenza MN. To do or not to do? The complexities of addiction, motivation, self-control, and impulsivity. Am J Psychiatry. 2007;164(1):4–6.

4. Chamberlain SR, Sahakian BJ. The neuropsychiatry of impulsivity. Curr Opin Psychiatry. 2007;20(3):255–61.

5. Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry. 2006;163(7):1282–9.

6. Wykes T, Haro JM, Bello SR, Obradors-Tarragó C, Arango C, Ayuso-Mateos JL, et al. Mental health research priorities for Europe. Lancet Psychiatry. 2015;2(11):1036–42.

7. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD; a systematic review and meta-regression analysis. Am J Psychiatry. 2007;164(3):942–8.

8. Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of prenatal unhealthy diet, insulin-like growth factor 2 gene (IGF2) methylation, and attention deficit hyperactivity disorder symptoms in youth with early-onset conduct problems. J Child Psychol Psychiatry. 2017;58(1):19–26.

9. Sarris J, Logan AC, Abbaraly TN, Amminger GP, Balanzá-Martínez V, Freeman MP, et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015;2(3):271–4.

10. Willatts P. Effects of nutrition on the development of higher-order cognition. Nestle Nutr Inst Workshop Ser. 2018;89:175–84.

11. Mohajeri MH, Troesch B, Weber P. Inadequate supply of vitamins and DHA – fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2014;35(9):1555–66.

12. Arteaga-Henríquez et al. Trials 2020;21:161

13. Borgo F, Riva A, Benetti A, Casiraghi MC, Bertelli S, Garbassa S, et al. Microbiota in anorexia nervosa: the triangle between bacterial species, metabolites and psychological tests. PLoS One. 2017;12(6):e0179739.

14. Felice VD, O’Mahony SM. The microbiome and disorders of the central nervous system. Pharmacol Biochem Behav. 2017;160:1–13.

15. O’Mahony SM, Clarke G, Dinan TG, Cryan JF. Early-life adversity and brain development: is the microbiome a missing piece of the puzzle? Neuroscience. 2017;342:27–54.

16. Stratci F, Cavaliere D, Albanese D, De Felice C, Donati C, Hayek J, et al. Altered gut microbiota in Rett syndrome. Microbiome. 2016;4:41.

17. Desbonnet L, Clarke G, Shanahan F, Dinan TG, Cryan JF. Microbiota is essential for social development in the mouse. Mol Psychiatry. 2014;19(2):146–8.

18. Tomova A, Husarova V, Lakatosova S, Bakos J, Vidova B, Babinska K, et al. Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav. 2015;138:79–87.

19. Wang L, Conlon MA, Christophersen CT, Sorich MJ, Anglety ML. Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders. Biomark Med. 2014;8(3):331–44.

20. Finegold SM, Downes I, Summanen PH. Microbiology of regressive autism. Anaerobe. 2012;18(2):260–2.

21. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16(4):444–53.

22. Parracho HM. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54(10):987–91.

23. Aarts E, Edeveren THA, Najaen J, Zwierts MP, Boekhorst J, Timmerman HM, et al. Gut microbiome in ADHD and its relation to neural reward anticipation. PLoS One. 2017;12(9):e0183509.

24. Petri A, Panagiotidou S, Hatzigeorgiou E, Stewart JM, Conti P, Theoharides TC. Gut-microbiota–brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):964–85.

25. Galley JD, Bailey MT. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes. 2014;5(3):390–6.

26. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiome on health and disease? Eur J Neurol. 2012;19(10):1701–12.

27. Ming X, Chen N, Ray C, Brewer G, Komnitzer J, Steer RA. A gut feeling: a hypothesis of the role of the microbiome in attention-deficits/ hyperactivity disorders. Child Neurol Open. 2018;5:2329048X18786789.

28. Mowry EM, Glenn JD. The dynamics of the gut microbiome in multiple sclerosis in relation to disease. Neurol Clin. 2018;36(1):185–96.

29. Stratci F, Cavaliere D, Albanese D, De Felice C, Donati C, Hayek J, et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5:24.

30. Storpe P, Hoffman M, Badali D, Colosimo C. Constipation: an emerging risk factor for Parkinson’s disease? Eur J Neurol. 2016;23(11):1606–13.

31. Wang YP, Chen YT, Tsai CF, Li SY, Luo SY, Wang SJ, et al. Short-term use of sorotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry. 2014;171(1):54–61.

32. Kang V, Wagner GC, Ming X. Gastrointestinal dysfunction in children with autism spectrum disorders. Autism Res. 2014;7(4):501–6.

33. McKeown C, Hisle-Gorman E, Eide M, Gorman GH, Nylund CM. Association of perceived stress and depression with an interaction between gut microbiota and socioemotional difficulties. Anaerobe. 2013;29:13–8.

34. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16(4):444–53.

35. Stratci F, Cavaliere D, Albanese D, De Felice C, Donati C, Hayek J, et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5:24.

36. Storpe P, Hoffman M, Badali D, Colosimo C. Constipation: an emerging risk factor for Parkinson’s disease? Eur J Neurol. 2016;23(11):1606–13.

37. Wang YP, Chen YT, Tsai CF, Li SY, Luo SY, Wang SJ, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry. 2014;171(1):54–61.

38. Kang V, Wagner GC, Ming X. Gastrointestinal dysfunction in children with autism spectrum disorders. Autism Res. 2014;7(4):501–6.

39. McKeown C, Hisle-Gorman E, Eide M, Gorman GH, Nylund CM. Association of perceived stress and depression with an interaction between gut microbiota and socioemotional difficulties. Anaerobe. 2013;29:13–8.

40. Knowles SR, Nelson EA, Palombo EA. Investigating the role of perceived stress on the interplay between commensal microbiota and host inflammation. Gut Microbes. 2014;5(3):390–6.
73. Gareau MG, Wine E, Rodrigues DM. Bacterial infection causes stress-induced memory dysfunction in mice. Gut. 2011;60:307–17.
74. Párry KA, Kalliomäki M, Wacklin P, Salminen S, Isolauri E. A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood: a randomized trial. Pediatr Res. 2015;77(6):823–8.
75. Yousefi B, Eslami M, Chasemian A, Kolhavi P, Salek Farrokh A, Drael N. Probiotics importance and their immunomodulatory properties. J Cell Physiol. 2018;234(6):8008–18.
76. Mardani F, Mahmoudi M, Esmaeili SA, Khorasani S, Tabasi N, Rastin M. In vivo study: Th1-Th2 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics. J Cell Physiol. 2018;234(6):642–9.
77. Tan M, Zhu JC, Du J, Zhang LM, Yin HH. Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic braininjured patients: a prospective randomized pilot study. Crit Care. 2011; 15(S):R290.
78. Tanabe S. The effect of probiotics and gut microbiota on Th17 cells. Int Rev Immunol. 2013;32(5-6):511–25.
79. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Moons H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration : guidance for protocols of clinical trials. BMJ. 2013; 346:e7586.